RxDoctor Payments Data

Kaitlyn Canova, APRN

Nurse Practitioner · Jupiter, FLNPI 1386363729

Payments from drug & device makers

$1,072in general payments, 2019–2025

Across 14 payments — averaging $76.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$244
  • Boston Scientific$168
  • Smith+Nephew$150
  • Orthofix Medical, Inc.$136
  • Intuitive Surgical$134
  • Axsome Therapeutics, Inc.$122
  • plus $120 from 4 others

What the payments were for

  • Food & beverage$1,072100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,072 in reported general payments places this provider in the 75th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$22,500
Medicare patients
158
Services billed
256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin43$70,236
OzempicSemaglutide31$48,227
EliquisApixaban35$37,826
Soliqua 100-33Insulin Glargine/Lixisenatide14$19,395
MounjaroTirzepatide19$19,148
XareltoRivaroxaban11$18,315
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,088
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$1,977
Atorvastatin Calcium131$1,281
Albuterol Sulfate HfaAlbuterol Sulfate43$1,272
Rosuvastatin Calcium105$851
Gabapentin48$833
Losartan Potassium78$752
Metoprolol Succinate45$704
Valsartan22$662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$22$70,23643 claims
Novo NordiskOzempic$23$48,22731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Jupiter

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →